暗盘情报 | “创新制药公司”迈威生物-B现涨超6%，一手赚332港元

富途资讯4月27日消息，$迈威生物-B (02493.HK)$暗盘现涨6.01%，报29.3港元，每手200股，不计手续费，一手332赚港元。

行情来源：富途证券

公司概况

公司是一家以药物研发方面的创新能力以及从药物发现至商业化销售的端到端运营能力而闻名的中国制药公司。公司的管线专注于肿瘤和年龄相关疾病，该等疾病在全球构成重大健康风险且存在未被满足的临床需求。

公司建立了具有竞争力的管线产品组合，包括不同品种的4款已上市产品及10款候选药物（1款处于NDA阶段、8款处于临床阶段及1款处于临床前阶段），专注于肿瘤和年龄相关疾病，如免疫、眼科、骨科等领域。公司的核心产品9MW2821（BFv，一款靶向Nectin-4ADC）为公司的其中一款ADC技术产品，体现了公司在该领域的专业知识。

财务概况

于2024年及2025年，公司分别录得收入人民币199.6百万元及人民币659.0百万元；公司的研发成本由2024年的人民币782.9百万元增至2025年的人民币977.0百万元；公司的毛利由2024年的人民币169.2百万元增至2025年的人民币596.4百万元。

$迈威生物-B(02493)$

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

石幽
04-27
石幽
中签的兄弟先别卖，再看看再说。
- 甜甜小:
  一手才赚三百，手续费扣完吃个盒饭。
寂寞如红酒
04-27
寂寞如红酒
一手赚三百多，可以了，明天别跌回去就行。[龇牙]
周紫心儿
04-27
周紫心儿
药股最近都半死不活，能红就不错了。

发表看法

4

15

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":558066067141048,"tweetId":"558066067141048","gmtCreate":1777278293999,"gmtModify":1777278703996,"author":{"id":4142984412645600,"idStr":"4142984412645600","authorId":4142984412645600,"authorIdStr":"4142984412645600","name":"三十观市","avatar":"https://static.tigerbbs.com/bcf9daf130625a08e521ed83c608168d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"a97bce155cb14045be40c3fe246e8d20-1","templateUuid":"a97bce155cb14045be40c3fe246e8d20","name":"新晋创作者","description":"首次获得精华帖的创作者","bigImgUrl":"https://static.tigerbbs.com/4ce9180a952c61a51c39f70d533b81a7","smallImgUrl":"https://static.tigerbbs.com/f98cf16cf4b858114f7ab9a779f9e6f1","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.05.26","individualDisplayEnabled":0},"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.02","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"wearingBadges":[{"badgeId":"a97bce155cb14045be40c3fe246e8d20-1","name":"新晋创作者","description":"首次获得精华帖的创作者","smallImgUrl":"https://static.tigerbbs.com/f98cf16cf4b858114f7ab9a779f9e6f1","bigImgUrl":"https://static.tigerbbs.com/4ce9180a952c61a51c39f70d533b81a7","isScarce":0,"effectEnabled":0,"redirectLinkEnabled":0,"redirectLinkValidityFrom":0,"redirectLinkValidityTo":9223372036854776000}],"fanSize":79,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/4cb5457bf314b79fae16cda4b0614ee8","width":"341","height":"424"},{"img":"https://static.tigerbbs.com/9b2f5681634c352bdd351e137f7e7aee","width":"645","height":"478"}],"coverImages":[{"img":"https://static.tigerbbs.com/4cb5457bf314b79fae16cda4b0614ee8","width":"341","height":"424"}],"title":"暗盘情报 | “创新制药公司”迈威生物-B现涨超6%，一手赚332港元","html":"<html><head></head><body><p>富途资讯4月27日消息，$迈威生物-B (02493.HK)$暗盘现涨6.01%，报29.3港元，每手200股，不计手续费，一手332赚港元。</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4cb5457bf314b79fae16cda4b0614ee8\" tg-width=\"341\" tg-height=\"424\"><span>行情来源：富途证券</span></p>\n<p style=\"text-align: justify;\"><strong>公司概况</strong></p>\n<p style=\"text-align: justify;\">公司是一家以药物研发方面的创新能力以及从药物发现至商业化销售的端到端运营能力而闻名的中国制药公司。公司的管线专注于肿瘤和年龄相关疾病，该等疾病在全球构成重大健康风险且存在未被满足的临床需求。</p>\n<p style=\"text-align: justify;\">公司建立了具有竞争力的管线产品组合，包括不同品种的4款已上市产品及10款候选药物（1款处于NDA阶段、8款处于临床阶段及1款处于临床前阶段），专注于肿瘤和年龄相关疾病，如免疫、眼科、骨科等领域。公司的核心产品9MW2821（BFv，一款靶向Nectin-4ADC）为公司的其中一款ADC技术产品，体现了公司在该领域的专业知识。</p>\n<p style=\"text-align: justify;\"><strong>财务概况</strong></p>\n<p style=\"text-align: justify;\">于2024年及2025年，公司分别录得收入人民币199.6百万元及人民币659.0百万元；公司的研发成本由2024年的人民币782.9百万元增至2025年的人民币977.0百万元；公司的毛利由2024年的人民币169.2百万元增至2025年的人民币596.4百万元。</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9b2f5681634c352bdd351e137f7e7aee\" tg-width=\"645\" tg-height=\"478\"></p>\n<p><a href=\"https://laohu8.com/S/02493\">$迈威生物-B(02493)$</a></p></body></html>","htmlText":"<html><head></head><body><p>富途资讯4月27日消息，$迈威生物-B (02493.HK)$暗盘现涨6.01%，报29.3港元，每手200股，不计手续费，一手332赚港元。</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4cb5457bf314b79fae16cda4b0614ee8\" tg-width=\"341\" tg-height=\"424\"><span>行情来源：富途证券</span></p>\n<p style=\"text-align: justify;\"><strong>公司概况</strong></p>\n<p style=\"text-align: justify;\">公司是一家以药物研发方面的创新能力以及从药物发现至商业化销售的端到端运营能力而闻名的中国制药公司。公司的管线专注于肿瘤和年龄相关疾病，该等疾病在全球构成重大健康风险且存在未被满足的临床需求。</p>\n<p style=\"text-align: justify;\">公司建立了具有竞争力的管线产品组合，包括不同品种的4款已上市产品及10款候选药物（1款处于NDA阶段、8款处于临床阶段及1款处于临床前阶段），专注于肿瘤和年龄相关疾病，如免疫、眼科、骨科等领域。公司的核心产品9MW2821（BFv，一款靶向Nectin-4ADC）为公司的其中一款ADC技术产品，体现了公司在该领域的专业知识。</p>\n<p style=\"text-align: justify;\"><strong>财务概况</strong></p>\n<p style=\"text-align: justify;\">于2024年及2025年，公司分别录得收入人民币199.6百万元及人民币659.0百万元；公司的研发成本由2024年的人民币782.9百万元增至2025年的人民币977.0百万元；公司的毛利由2024年的人民币169.2百万元增至2025年的人民币596.4百万元。</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9b2f5681634c352bdd351e137f7e7aee\" tg-width=\"645\" tg-height=\"478\"></p>\n<p><a href=\"https://laohu8.com/S/02493\">$迈威生物-B(02493)$</a></p></body></html>","text":"富途资讯4月27日消息，$迈威生物-B (02493.HK)$暗盘现涨6.01%，报29.3港元，每手200股，不计手续费，一手332赚港元。 行情来源：富途证券 公司概况 公司是一家以药物研发方面的创新能力以及从药物发现至商业化销售的端到端运营能力而闻名的中国制药公司。公司的管线专注于肿瘤和年龄相关疾病，该等疾病在全球构成重大健康风险且存在未被满足的临床需求。 公司建立了具有竞争力的管线产品组合，包括不同品种的4款已上市产品及10款候选药物（1款处于NDA阶段、8款处于临床阶段及1款处于临床前阶段），专注于肿瘤和年龄相关疾病，如免疫、眼科、骨科等领域。公司的核心产品9MW2821（BFv，一款靶向Nectin-4ADC）为公司的其中一款ADC技术产品，体现了公司在该领域的专业知识。 财务概况 于2024年及2025年，公司分别录得收入人民币199.6百万元及人民币659.0百万元；公司的研发成本由2024年的人民币782.9百万元增至2025年的人民币977.0百万元；公司的毛利由2024年的人民币169.2百万元增至2025年的人民币596.4百万元。 $迈威生物-B(02493)$","highlighted":1,"essential":1,"paper":2,"likeSize":15,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/558066067141048","repostId":0,"isVote":1,"tweetType":1,"viewCount":1020,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02493","688062"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":828,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":558075653449728,"commentId":"558075653449728","gmtCreate":1777280718128,"gmtModify":1777280721930,"authorId":4130491074501500,"author":{"id":4130491074501500,"idStr":"4130491074501500","authorId":4130491074501500,"name":"石幽","avatar":"https://static.tigerbbs.com/35abfb387b646fb639e8a59226ec46e6","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":558066067141048,"objectIdStr":"558066067141048","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"中签的兄弟先别卖，再看看再说。\n<br>","text":"中签的兄弟先别卖，再看看再说。\n<br>","html":"中签的兄弟先别卖，再看看再说。\n<br>","likeSize":0,"commentSize":1,"subComments":[{"id":558076033336224,"commentId":"558076033336224","gmtCreate":1777280731018,"gmtModify":1777280735844,"authorId":4130491029501360,"author":{"id":4130491029501360,"idStr":"4130491029501360","authorId":4130491029501360,"name":"甜甜小","avatar":"https://static.tigerbbs.com/25fc231df4362a5cdc318177a8de3233","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":558066067141048,"objectIdStr":"558066067141048","type":1,"supId":558075653449728,"supIdStr":"558075653449728","prevId":0,"prevIdStr":"0","content":"一手才赚三百，手续费扣完吃个盒饭。\n<br>","text":"一手才赚三百，手续费扣完吃个盒饭。\n<br>","html":"一手才赚三百，手续费扣完吃个盒饭。\n<br>","disclaimerType":0}],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":558076039325136,"commentId":"558076039325136","gmtCreate":1777280744634,"gmtModify":1777280748909,"authorId":4130491647501850,"author":{"id":4130491647501850,"idStr":"4130491647501850","authorId":4130491647501850,"name":"寂寞如红酒","avatar":"https://static.tigerbbs.com/65c631d608d204ac37af91dd7acc8e0d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":558066067141048,"objectIdStr":"558066067141048","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"一手赚三百多，可以了，明天别跌回去就行。[龇牙]\n<br>","text":"一手赚三百多，可以了，明天别跌回去就行。[龇牙]\n<br>","html":"一手赚三百多，可以了，明天别跌回去就行。[龇牙]\n<br>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":558075849053808,"commentId":"558075849053808","gmtCreate":1777280711098,"gmtModify":1777280715842,"authorId":4130490946501150,"author":{"id":4130490946501150,"idStr":"4130490946501150","authorId":4130490946501150,"name":"周紫心儿","avatar":"https://static.tigerbbs.com/d4b9cb05e28d76eb4572bf625f3e6a28","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[]},"repliedAuthorId":0,"objectId":558066067141048,"objectIdStr":"558066067141048","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"药股最近都半死不活，能红就不错了。","text":"药股最近都半死不活，能红就不错了。","html":"药股最近都半死不活，能红就不错了。","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/558066067141048"}